Chris co-founded Clinipace Worldwide and currently services as president and general counsel. In this role, Chris leads corporate and business development, legal affairs, medical affairs, human resources, therapeutic leadership, regulatory & strategic development, and corporate quality assurance.
Prior to Clinipace Worldwide, Chris Porter served as vice president of corporate development & legal affairs for Drug Safety Alliance, Inc. (DSA). Additionally, Chris served as group manager of the Siebel Venture Group, Siebel Systems, Inc. where he was responsible for all of Siebel's venture transactions and management of a $30M portfolio with a specific interest in Life Science technology opportunities. Chris joined Siebel through Siebel's $542M acquisition of OpenSite Technologies where Chris was the original member of the business development group.
Chris has held various other positions in the life science industry including positions in sales and marketing for Glaxo, Inc. and Quintiles Transnational, and manager of legal & business affairs for AM Pappas & Associates, one of the largest life science venture capital firms in the Southeast.
Chris received his Juris Doctor and Masters of Business Administration from the University of North Carolina at Chapel Hill in 1998. Chris also earned his BA in Journalism/Advertising from UNC-CH in 1992.
In 2008 Chris was named to the PharmaVoice 100, an annual listing of the 100 most influential people in the life sciences industry.